[1] J.S. Weber, S.P. D’Angelo, D. Minor, F.S. Hodi, R. Gutzmer, B. Neyns, C. Hoeller, N.
I. Khushalani, W.H. Miller, C.D. Lao, G.P. Linette, L. Thomas, P. Lorigan, K.
F. Grossmann, J.C. Hassel, M. Maio, M. Sznol, P.A. Ascierto, P. Mohr,
B. Chmielowski, A. Bryce, I.M. Svane, J.-J. Grob, A.M. Krackhardt, C. Horak,
A. Lambert, A.S. Yang, J. Larkin, Nivolumab versus chemotherapy in patients with
advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate
037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol. 16 (2015)
375–384.
[2] E.B. Garon, N.A. Rizvi, R. Hui, N. Leighl, A.S. Balmanoukian, J.P. Eder, A. Patnaik,
C. Aggarwal, M. Gubens, L. Horn, E. Carcereny, M.-J. Ahn, E. Felip, J.-S. Lee, M.
D. Hellmann, O. Hamid, J.W. Goldman, J.-C. Soria, M. Dolled-Filhart, R.
Z. Rutledge, J. Zhang, J.K. Lunceford, R. Rangwala, G.M. Lubiniecki, C. Roach,
K. Emancipator, Gandhi L for the KEYNOTE-001 Investigators. Pembrolizumab for
the treatment of non–small-cell lung cancer, N. Engl. J. Med. 372 (2015)
2018–2028.
[3] H. Borghaei, L. Paz-Ares, L. Horn, D.R. Spigel, M. Steins, N.E. Ready, L.Q. Chow, E.
E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhaufl, O. Arrietta, M.A. Burgio,
FayetteJ, H. Lena, E. Poddubskaya, D.E. Gerber, S.N. Gettinger, C.M. Rudin,
N. Rizvi, L. Crino, G.R. Blumenschein Jr., S.J. Antonia, C. Dorange, C.T. Harbison,
F.G. Finckenstein, J.R. Brahmer, Nivolumab versus docetaxel in advanced
nonsquamous non–small-cell lung cancer, N. Engl. J. Med. 373 (2015) 1627–1639.
[4] J. Brahmer, K.L. Reckamp, P. Baas, L. Crino, W.E.E. Eberhardt, E. Poddubskaya,
S. Antonia, A. Pluzanski, E.E. Vokes, E. Holgado, D. Waterhouse, N. Ready,
119
N. Yorita et al.
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
Cancer Letters 498 (2021) 111–120
J. Gainor, O.A. Frontera, L. Havel, M. Steins, M.C. Garassino, J.G. Aerts,
M. Domine, L. Paz-Ares, M. Reck, C. Baudelet, C.T. Harbison, B. Lestini, D.
R. Spigel, Nivolumab versus docetaxel in advanced squamous-cell non–small-cell
lung cancer, N. Engl. J. Med. 3 73 (2015) 123–135.
Cancer Genome Atlas Network, Comprehensive molecular characterization of
human colon and rectal cancer, Nature 487 (2012) 330–337.
R. Gryfe, H. Kim, E.T.K. Hsieh, M.D. Aronson, E.J. Holowaty, S.B. Bull, M. Redston,
S. Gallinger, Tumor microsatellite instability and clinical outcome in young
patients with colorectal cancer, N. Engl. J. Med. 342 (2000) 69–77.
L. Gandhi, D. Rodríguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. De Angelis,
M. Domine, P. Clingan, M.J. Hochmair, S.F. Powell, S.Y. Cheng, H.G. Bischoff,
N. Peled, F. Grossi, R.R. Jennens, M. Reck, R. Hui, E.B. Garon, M. Boyer, B. RubioViqueira, S. Novello, T. Kurata, J.E. Gray, J. Vida, Z. Wei, J. Yang, H. Raftopoulos,
M.C. Pietanza, M.C. Garassino, KEYNOTE-189 investigators. Pembrolizumab plus
chemotherapy in metastatic non-small-cell lung cancer, N. Engl. J. Med. 378
(2018) 2078–2092.
C.J. Langer, S.M. Gadgeel, H. Borghaei, V.A. Papadimitrakopoulou, A. Patnaik, S.
F. Powell, R.D. Gentzler, R.G. Martins, J.P. Stevenson, S.I. Jalal, A. Panwalkar, J.
C. Yang, M. Gubens, L.V. Sequist, M.M. Awad, J. Fiore, Y. Ge, H. Raftopoulos,
L. Gandhi, KEYNOTE-021 investigators. Carboplatin and pemetrexed with or
without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a
randomised, phase 2 cohort of the open-label KEYNOTE-021 study, Lancet Oncol.
17 (2016) 1497–1508.
G. Bindea, B. Mlecnik, M. Tosolini, A. Kirilovsky, M. Waldner, A.C. Obenauf,
H. Angell, T. Fredriksen, L. Lafontaine, A. Berger, P. Bruneval, W.H. Fridman,
C. Becker, F. Pages, M.R. Speicher, Z. Trajanoski, J. Galon, Spatiotemporal
dynamics of intratumoral immune cells reveal the immune landscape in human
cancer, Immunity 39 (2013) 782–795.
J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pages,
M. Tosolini, M. Camus, A. Berger, P. Wind, F. Zinzindohoue, P. Bruneval, P.H. Cugnenc, Z. Trajanoski, W.-H. Fridman, F. Pages, Type, density, and location of
immune cells within human colorectal tumors predict clinical outcome, Science
313 (2006) 1960–1964.
F. Pag`es, A. Berger, M. Camus, F. Sanchez-Cabo, A. Costes, R. Molidor, B. Mlecnik,
A. Kirilovsky, M. Nilsson, D. Damotte, T. Meatchi, P. Bruneval, P.-H. Cugnenc,
Z. Trajanoski, W.-H. Fridman, J. Galon, Effector memory T cells, early metastasis,
and survival in colorectal cancer, N. Engl. J. Med. 353 (2005) 2654–2666.
L. Ziani, S. Chouaib, J. Thiery, Alteration of the antitumor immune response by
cancer-associated fibroblasts, Front. Immunol. 9 (2018) 414.
A. Orimo, P.B. Gupta, D.C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. Naeem, V.
J. Carey, A.L. Richardson, R.A. Weinberg, Stromal fibroblasts present in invasive
human breast carcinomas promote tumor growth and angiogenesis through
elevated SDF-1/CXCL12 secretion, Cell 121 (2005) 335–348.
Y. Kitadai, T. Sasaki, T. Kuwai, T. Nakamura, C.D. Bucana, S.R. Hamilton, I.
J. Fidler, Expression of activated platelet-derived growth factor receptor in stromal
cells of human colon carcinomas is associated with metastatic potential, Int. J.
Canc. 119 (2006) 2567–2574.
Olivier De Wever, M. Mareel, Role of tissue stroma in cancer cell invasion,
J. Pathol. 200 (2003) 429–447.
R. Yuge, Y. Kitadai, K. Shinagawa, M. Onoyama, S. Tanaka, W. Yasui, K. Chayama,
mTOR and PDGF pathway blockade inhibits liver metastasis of colorectal cancer by
modulating the tumor microenvironment, Am. J. Pathol. 185 (2015) 399–408.
H. Takigawa, Y. Kitadai, K. Shinagawa, R. Yuge, Y. Higashi, S. Tanaka, W. Yasui,
K. Chayama, Multikinase inhibitor regorafenib inhibits the growth and metastasis
of colon cancer with abundant stroma, Canc. Sci. 107 (2016) 601–608.
R. Yuge, Y. Kitadai, H. Takigawa, T. Naito, N. Oue, W. Yasui, S. Tanaka,
K. Chayama, Silencing of discoidin domain receptor-1 (DDR1) concurrently
inhibits multiple steps of metastasis cascade in gastric cancer, Transl Oncol 11
(2018) 575–584.
T.F. Gajewski, The next hurdle in cancer immunotherapy: overcoming the non–Tcell-inflamed tumor microenvironment, Semin. Oncol. 42 (2015) 663–671.
P.S. Hegde, V. Karanikas, S. Evers, The where, the when, and the how of immune
monitoring for cancer immunotherapies in the era of checkpoint inhibition, Clin.
Canc. Res. 22 (2016) 1865–1874.
F. Pages, B. Mlecnik, F. Marliot, G. Bindea, F.S. Ou, C. Bifulco, A. Lugli, I. Zlobec, T.
T. Rau, M.D. Berger, I.D. Nagtegaal, E. Vink-B¨
orger, A. Hartmann, C. Geppert,
J. Kolwelter, S. Merkel, R. Grützmann, M. Van den Eynde, A. Jouret-Mourin,
A. Kartheuser, D. L´eonard, C. Remue, J.Y. Wang, P. Bavi, M.H.A. Roehrl, P.
S. Ohashi, L.T. Nguyen, S. Han, H.L. MacGregor, S. Hafezi-Bakhtiari, B.G. Wouters,
G.V. Masucci, E.K. Andersson, E. Zavadova, M. Vocka, J. Spacek, L. Petruzelka,
B. Konopasek, P. Dundr, H. Skalova, K. Nemejcova, G. Botti, F. Tatangelo, P. Delrio,
G. Ciliberto, M. Maio, L. Laghi, F. Grizzi, T. Fredriksen, B. Buttard, M. Angelova,
A. Vasaturo, P. Maby, S.E. Church, H.K. Angell, L. Lafontaine, D. Bruni, C. El Sissy,
N. Haicheur, A. Kirilovsky, A. Berger, C. Lagorce, J.P. Meyers, C. Paustian, Z. Feng,
C. Ballesteros-Merino, J. Dijkstra, C. van de Water, S. van Lent-van Vliet, N. Knijn,
A. Mușin˘
a, D. Scripcariu, B. Popivanova, M. Xu, T. Fujita, S. Hazama, N. Suzuki,
H. Nagano, K. Okuno, T. Torigoe, N. Sato, T. Furuhata, I. Takemasa, K. Itoh, P.
S. Patel, H.H. Vora, B. Shah, J.B. Patel, K.N. Rajvik, S.J. Pandya, S.N. Shukla,
Y. Wang, G. Zhang, Y. Kawakami, F.M. Marincola, P.A. Ascierto, D.J. Sargent, B.
A. Fox, J. Galon, International validation of the consensus Immunoscore for the
classification of colon cancer: a prognostic and accuracy study, Lancet 391 (2018)
2128–2139.
[22] E. Lanitis, M. Irving, G. Coukos, Targeting the tumor vasculature to enhance T cell
activity, Curr. Opin. Immunol. 33 (2015) 55–63.
[23] L.Y. Tan, C. Martini, Z.G. Fridlender, C.S. Bonder, M.P. Brown, L.M. Ebert, Control
of immune cell entry through the tumour vasculature: a missing link in optimising
melanoma immunotherapy? Clin Transl Immunol 6 (2017) e134.
[24] N. Nagarsheth, M.S. Wicha, W. Zou, Chemokines in the cancer microenvironment
and their relevance in cancer immunotherapy, Nat. Rev. Immunol. 17 (2017)
559–572.
[25] M. Camus, M. Tosolini, B. Mlecnik, F. Pages, A. Kirilovsky, A. Berger, A. Costes,
G. Bindea, P. Charoentong, P. Bruneval, Z. Trajanoski, W.-H. Fridman, J. Galon,
Coordination of intratumoral immune reaction and human colorectal cancer
recurrence, Canc. Res. 69 (2009) 2685–2693.
[26] H. Tang, Y. Wang, L.K. Chlewicki, Y. Zhang, J. Guo, W. Liang, J. Wang, X. Wang,
Y.-X. Fu, Facilitating T cell infiltration in tumor microenvironment overcomes
resistance to PD-L1 blockade, Canc. Cell 29 (2016) 285–296.
[27] T. Sumida, Y. Kitadai, K. Shinagawa, M. Tanaka, M. Kodama, M. Ohnishi, E. Ohara,
S. Tanaka, W. Yasui, K. Chayama, Anti-stromal therapy with imatinib inhibits
growth and metastasis of gastric carcinoma in an orthotopic nude mouse model,
Int. J. Canc. 128 (2011) 2050–2062.
[28] E. Vilar, S.B. Gruber, Microsatellite instability in colorectal cancer–the stable
evidence, Nat. Rev. Clin. Oncol. 7 (2010) 153–162.
[29] N.M. Lindor, L.J. Burgart, O. Leontovich, R.M. Goldberg, J.M. Cunningham, D.
J. Sargent, C. Walsh-Vockley, G.M. Petersen, M.D. Walsh, B.A. Leggett, J.P. Young,
M.A. Barker, J.R. Jass, J. Hopper, S. Gallinger, B. Bapat, M. Redston, S.
N. Thibodeau, Immunohistochemistry versus microsatellite instability testing in
phenotyping colorectal tumors, J. Clin. Oncol. 20 (2002) 1043–1048.
[30] T.C. Smyrk, P. Watson, K. Kaul, H.T. Lynch, Tumor-infiltrating lymphocytes are a
marker for microsatellite instability in colorectal carcinoma, Cancer 91 (2001)
2417–2422.
[31] Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 15545–15550.
[32] P.C. Tumeh, C.L. Harview, J.H. Yearly, I.P. Shintaku, E.J.M. Taylor, L. Robert,
B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, A.N. West, M. Carmona,
C. Kivork, E. Seja, G. Cherry, A.J. Gutierrez, T.R. Grogan, C. Mateus, G. Tomasic, J.
A. Glaspy, R.O. Emerson, H. Robins, R.H. Pierce, D.A. Elashoff, C. Robert, A. Ribas,
PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature
515 (2014) 568–571.
[33] S. Spranger, R. Bao, T.F. Gajewski, Melanoma- intrinsic beta-catenin signalling
prevents anti-tumour immunity, Nature 523 (2015) 231–235.
[34] T. Iwata-Kajihara, H. Sumimoto, N. Kawamura, R. Ueda, T. Takahashi,
H. Mizuguchi, M. Miyagishi, K. Takeda, Y. Kawakami, Enhanced cancer
immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing
ability and resistance to cancer cell-derived inhibitory factors, J. Immunol. 187
(2011) 27–36.
[35] B. Mlecnik, G. Bindea, H.K. Angell, P. Maby, M. Angelova, D. Tougeron, S.
E. Church, L. Lafontaine, M. Fischer, T. Fredriksen, M. Sasso, A.M. Bilocq,
A. Kirilovsky, A.C. Obenauf, M. Hamieh, A. Berger, P. Bruneval, J.-J. Tuech, J.C. Sabourin, F. Le Pessot, J. Mauillon, A. Rafii, P. Laurent-Puig, M.R. Speicher,
Z. Trajanoski, P. Michel, R. Sesboue, T. Frebourg, F. Pages, V. Valge-Archer, J.B. Latouche, J. Galon, Integrative analyses of colorectal cancer show immunoscore
is a stronger predictor of patient survival than microsatellite instability, Immunity
44 (2016) 698–711.
[36] D.S. Williams, M.J. Bird, R.N. Jorissen, Y.L. Yu, F. Walker, H.H. Zhang, E.C. Nice,
BurgessAW, Nonsense mediated decay resistant mutations are a source of
expressed mutant proteins in colon cancer cell lines with microsatellite instability,
PloS One 5 (2010), e16012.
[37] D.T. Le, J.N. Uram, H. Wang, B. Bartlett, H. Kemberling, A. Eyring, N.S. Azad,
D. Laheru, R.C. Donehower, T.S. Crocenzi, R.M. Goldberg, G.A. Fisher, J.J. Lee, T.
F. Greten, M. Koshiji, S.P. Kang, R.A. Anders, J.R. Eshleman, B. Vogelstein, L.
A. Diaz, Programmed death-1 blockade in mismatch repair deficient colorectal
cancer, J. Clin. Oncol. 34 (15_suppl) (2016) 103.
[38] J. Paulsson, T. Sj¨
oblom, P. Micke, F. Ponten, G. Landberg, C.-H. Heldin, J. Bergh, D.
J. Brennan, K. Jirstrom, A. Ostman, Prognostic significance of stromal plateletderived growth factor beta-receptor expression in human breast cancer, Am. J.
Pathol. 175 (2009) 334–341.
[39] G. Lindmark, C. Sundberg, B. Glimelius, L. Pahlman, K. Rubin, B. Gerdin, Stromal
expression of platelet-derived growth factor beta-receptor and platelet-derived
growth factor B-chain in colorectal cancer, Lab. Invest. 69 (1993) 682–689.
[40] H.N. Antoniades, T. Galanopoulos, J. Neville-Golden, C.J. O’Hara, Malignant
epithelial cells in primary human lung carcinomas coexpress in vivo plateletderived growth factor (PDGF) and PDGF receptor mRNAs and their protein
products, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 3942–3946.
[41] M. Onoyama, Y. Kitadai, Y. Tanaka, R. Yuge, K. Shinagawa, S. Tanaka, W. Yasui,
K. Chayama, Combining molecular targeted drugs to inhibit both cancer cells and
activated stromal cells in gastric cancer, Neoplasia 15 (2013) 1391–1399.
[42] K. Pietras, A. Ostman,
M. Sj¨
oquist, E. Buchdunger, R.K. Reed, C.-H. Heldin,
K. Rubin, Inhibition of platelet-derived growth factor receptors reduces interstitial
hypertension and increases transcapillary transport in tumors, Canc. Res. 61
(2001) 2929–2934.
[43] K. Pietras, Increasing tumor uptake of anticancer drugs with imatinib, Semin.
Oncol. 31 (2004) 18–23.
120
...
論文の公開元へ
